Stocktoria
PROCEPT BioRobotics Corp PRCT
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-09-15
PROCEPT BioRobotics Corp financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M | $7.7M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M | -$1.3M |
| R&D expense | $71.3M | $62.3M | $48.4M | $29.0M | $19.0M | $16.3M |
| SG&A expense | $228.8M | $171.4M | $131.8M | $88.8M | $51.0M | $30.3M |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M | -$54.2M | -$47.8M |
| Interest expense | — | — | $4.0M | $5.2M | $5.8M | $5.3M |
| Income tax | $190,000 | $368,000 | $80,000 | $0 | $0 | $0 |
| Net income | -$95.6M | -$91.4M | -$105.9M | -$87.2M | -$59.9M | -$53.0M |
| EPS (diluted) | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 | $-14.47 |
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M | -$57.3M | -$48.3M |
| Free cash flow | -$58.3M | -$103.6M | -$133.2M | -$83.0M | -$57.9M | -$48.6M |
| Cash & equivalents | $286.5M | $333.7M | $257.2M | $221.9M | $304.3M | $100.1M |
| Inventory | $70.7M | $56.2M | $39.8M | $28.5M | $13.1M | $6.9M |
| Total assets | $508.1M | $534.0M | $404.7M | $309.3M | $337.0M | $126.0M |
| Total liabilities | $142.2M | $131.8M | $124.0M | $112.3M | $69.9M | $65.0M |
| Shareholders' equity | $365.9M | $402.2M | $280.8M | $197.1M | $267.1M | -$182.9M |
Growth · year-over-year · Revenue CAGR 109%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +37.2% | +64.8% | +81.6% | +117.6% | +346.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.